908 Devices Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -65.2% over 5Y.
today you would have $351.78▼ -64.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $5.25 | $2.20 | $11.22 | $7.62 | $25.87 | $56.95 | |
| P/E | — | 9.7x | — | — | — | — | — |
| P/S | 6.3x | 3.5x | 1.6x | 7.4x | 5.2x | 19.1x | 57.8x |
| P/B | 1.8x | 1.4x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CARLCarlsmed Inc | $16.88 | — | 5.5x | — | -66.14% | $460.87M |
| SCTXScribe Therapeutics, Inc. | $28.44 | — | — | — | — | $460.22M |
| SGHTSight Sciences, Inc. | $8.50 | — | 8.8x | — | -48.42% | $468.25M |
| AVIRAtea Pharmaceuticals, Inc. | $5.64 |
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Company description provided by Yahoo Finance.
| 0.7x |
| 2.2x |
| 1.3x |
| 3.8x |
| 11.2x |
| EPS | $0.54 | -$2.12 | -$1.13 | -$1.07 | -$0.79 | -$2.35 |
| Profit margin | -62.08% | 34.68% | -151.23% | -72.47% | -71.64% | -52.53% | -47.66% |
| ROE | -13.97% | 13.56% | -63.01% | -21.99% | -17.61% | -10.33% | -9.22% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 2.2x |
| — |
| -58.14% |
| $452.35M |
| SRTAStrata Critical Medical, Inc. | $5.34 | — | 1.7x | — | -9.22% | $472.41M |
| CLPTClearPoint Neuro, Inc. | $15.55 | — | 44.1x | — | -226.52% | $474.34M |